文献速递类风湿关节炎

类风湿关节炎患者接受Janus激酶抑制剂或bDMARDs治疗的新发恶性肿瘤风险比较:德国RABBIT登记处的观察性数据

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register.
PubMed 文献 · Ann Rheum Dis · 2025-06-26

基于德国RABBIT登记处2017年1月至2020年12月启动的2285例JAKi和4259例bDMARD治疗 episodes,随访至2024年6月,JAKi组发生88例、bDMARD组135例恶性肿瘤。JAKi组发病率11.6/1000患者年(95%CI 9.3,14.3),bDMARD组8.9/1000患者年(95%CI 7.4,10.5),调整后HR为1.40(95%CI 1.09,1.80)。仅在治疗持续超过16个月的治疗episodes中观察到JAKi较bDMARD的恶性肿瘤风险增加,且风险在部分亚组中似乎更高。

要点

  • JAKi组恶性肿瘤发病率为11.6/1000患者年,bDMARD组为8.9/1000患者年。
  • 调整后JAKi较bDMARD的恶性肿瘤风险HR为1.40(95%CI 1.09,1.80)。
  • 仅在治疗持续时间超过16个月的治疗episodes中观察到JAKi较bDMARD的恶性肿瘤风险增加。

核心结论

  • 在这项德国观察性队列研究中,JAKi较bDMARD治疗的恶性肿瘤风险总体小幅增加,部分患者亚组风险更明显。
  • 观察到的风险应与疾病控制不足相关的已知恶性肿瘤风险仔细权衡。

研究设计与样本

  • 分析德国RABBIT登记处2017年1月至2020年12月启动、随访至2024年6月的DMARD治疗episodes,纳入2285例JAKi和4259例bDMARD治疗episodes。
  • 计算每1000患者年的发病率及95%CI,采用逆概率加权调整Cox模型估计恶性肿瘤风险的风险比(HR)。

主要发现

  • JAKi组发生88例恶性肿瘤,bDMARD组发生135例。
  • JAKi组发病率为11.6/1000患者年(95%CI 9.3,14.3),bDMARD组为8.9/1000患者年(95%CI 7.4,10.5)。
  • 调整后JAKi对比bDMARD的HR为1.40(95%CI 1.09,1.80)。
  • 仅在治疗持续时间超过16个月的治疗episodes中观察到JAKi较bDMARD的恶性肿瘤风险增加。
  • 在开始治疗年龄≥60岁、既往接受≥3种传统合成DMARD治疗以及高疾病活动的部分患者亚组中风险似乎更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the effects of Janus kinase inhibitors (JAKis) vs biologic disease-modifying antirheumatic drugs (bDMARDs) on the risk of incident malignancies (excluding nonmelanoma skin cancer) in patients and patient subgroups with rheumatoid arthritis. METHODS: Episodes of disease-modifying antirheumatic drug (DMARD) treatment initiated between January 2017 and December 2020 and followed up to June 2024 in RABBIT, the German register for the long-term observation of therapy with biologics and targeted disease-modifying antirheumatic drugs in adult patients with rheumatoid arthritis, were analysed. Incidence rates (IRs) per 1000 patient-years with 95% CIs were calculated, and incident malignancy risk was estimated as hazard ratios (HRs) by inverse probability weighted adjusted Cox models. RESULTS: Among 2285 JAKi and 4259 bDMARD treatment episodes, 88 and 135 malignancies occurred, respectively. JAKi treatments were dominated by baricitinib and tofacitinib, while most bDMARD treatments comprised tumour necrosis factor inhibitors. IRs were 11.6 (95% CI: 9.3, 14.3) in JAKi- and 8.9 (95% CI: 7.4, 10.5) in bDMARD-treated groups. The adjusted HR comparing JAKis with bDMARDs was 1.40 (95% CI: 1.09, 1.80). An increase in the malignancy risk for JAKi vs bDMARD treatment could only be observed in treatment episodes lasting longer than 16 months. The risk appeared higher in some subgroups of patients, including those who started treatment aged ≥60 years, patients with ≥3 prior conventional synthetic DMARD treatments, and patients with high disease activity. CONCLUSIONS: In this German observational cohort study, an overall small increase in malignancy risk for JAKi vs bDMARD treatment was observed, with more pronounced risks in some subgroups of patients. The observed risk should be carefully counterbalanced to the known malignancy risk associated with insufficient disease control.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Schaefer M, Purschke A, Zietemann V, et al. Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Ann Rheum Dis. 2025. PMID: 40571478. doi:10.1016/j.ard.2025.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。